Wedbush Reaffirms Rocket Pharma At Outperform With $16 Price Target

FDA granted accelerated approval for KRESLADI for Severe LAD-I and awarded Rocket a Rare Pediatric Disease PRV; the drug showed 100% overall survival at 12 months and through 18–24 months with all endpoints met and no treatment-related SAEs. Wedbush reiterated an Outperform and $16 12-month target, valuing the PRV at roughly $200M of non-dilutive funding; Rocket ended 2025 with ~$188.9M cash and runway into Q2 2027 excluding the PRV (management expects runway into 2028 including PRV). Despite the approval (March 26, 2026), the stock has fallen ~27% since approval and is trading at $3.44, down 8.62% intraday.

Analysis

This approval-path event reallocates value away from pure R&D optionality toward execution and commercialization bottlenecks; the immediate winners will be firms that control viral-vector and cell-processing capacity (CDMOs) as well as transplant centers that can operationalize complex infusions. Expect margin capture and pricing power at CDMOs to tighten over the next 6–18 months as customers pay up for validated, on-spec capacity, while smaller gene-therapy developers without in-house manufacturing face longer go-to-market timelines.

Market reaction appears driven more by financing and timing uncertainty than by the clinical dataset’s quality; the critical near-term catalysts are monetization of transferable regulatory assets, payer negotiation outcomes, and announced manufacturing scale-up plans. These are staggered events: asset monetization can be executed in days–months, contracting and hospital rollout in months–year, and durability/safety readouts that would materially re-rate the story occur over years.

Key tail risks are operational (manufacturing yield, batch failures), commercial (narrow formulary access or restrictive coverage policies), and macro (PRV buyers retrenching, compressing expected proceeds). Conversely, a swift sale of a transferable regulatory voucher or a partnership for manufacturing could force a 12–24 month runway reset and attract strategic acquirers, compressing upside capture windows for public investors.

From a positioning perspective, the market is pricing a high-probability dilution/delay scenario; that is a defensible view but prone to overshoot. A modest, hedged exposure that monetizes binary near-term events (voucher sale, JV/partnering, pricing announcement) captures asymmetric upside while limiting binary downside from long-term durability surprises.

Key Decisions for Investors

• Long RCKT sized 1–3% of portfolio with downside protection: buy shares and simultaneously purchase a 12-month put ~40% OTM to cap tail risk; target 2.5x upside if PRV monetization or strategic deal announced within 6–12 months, limit loss to put premium + delta exposure.
• Directional options play: buy a 12-month call spread on RCKT (bullish 150%/300% strikes) to keep cost low while retaining >3x upside if a catalyst (voucher sale or partnership) occurs within 6–12 months; budget premium as <1% notional risk.
• Pair trade to isolate idiosyncratic upside: long RCKT / short biotech ETF (IBB) for 6–12 months to hedge sector beta while keeping binary upside; target asymmetric payoff >2:1 if company-specific positives materialize.
• Tactical long on CDMOs (Catalent CTLT, Thermo Fisher TMO, Lonza LZAGY) for 6–18 months to capture capacity-rental premium as gene-therapy commercialization activity accelerates; expect more durable revenue uplift and lower binary risk than single-asset biotech exposure.